Koen Van Eygen

2.4k total citations · 1 hit paper
51 papers, 1.0k citations indexed

About

Koen Van Eygen is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Koen Van Eygen has authored 51 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 14 papers in Hematology and 12 papers in Oncology. Recurrent topics in Koen Van Eygen's work include Chronic Lymphocytic Leukemia Research (12 papers), Frailty in Older Adults (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Koen Van Eygen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Frailty in Older Adults (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Koen Van Eygen collaborates with scholars based in Belgium, United Kingdom and United States. Koen Van Eygen's co-authors include Pierre Zachée, Lucien Noens, Philippe Mineur, Sabina De Geest, Gregor Verhoef, Philippe Martiat, R. De Bock, Zwi Berneman, Ivo Abraham and Tara Albrecht and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Koen Van Eygen

47 papers receiving 985 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

2009 463 citations Lucien Noens, Gregor Verhoef et al. profile →

Peers

Countries citing papers authored by Koen Van Eygen

Since Specialization

Citations

This map shows the geographic impact of Koen Van Eygen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen Van Eygen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen Van Eygen more than expected).

Fields of papers citing papers by Koen Van Eygen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen Van Eygen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen Van Eygen. The network helps show where Koen Van Eygen may publish in the future.

Co-authorship network of co-authors of Koen Van Eygen

This figure shows the co-authorship network connecting the top 25 collaborators of Koen Van Eygen. A scholar is included among the top collaborators of Koen Van Eygen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koen Van Eygen. Koen Van Eygen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives 2024 ·SHILAP Revista de lepidopterología ·(unknown), Stef Meers, (unknown), (unknown), Koen Theunissen, Koen Van Eygen, Nathan De Beule, (unknown), (unknown), (unknown), Jan Lemmens, Ann Van de Velde, Dominik Selleslag, Jason Bouziotis, Ann De Becker, Sébastien Anguille	0
2	Acupuncture as a Complementary Therapy for Cancer Care: Acceptability and Preferences of Patients and Informal Caregivers 2021 ·Journal of Acupuncture and Meridian Studies ·(unknown), (unknown), (unknown), (unknown), Hans Pottel, Koen Van Eygen, Sofie Derijcke, Philippe Vergauwe, Pat Schofield, (unknown), (unknown), Tom Boterberg, Philip R. Debruyne	2
3	Oncologic Home-Hospitalization Delivers a High-Quality and Patient-Centered Alternative to Standard Ambulatory Care: Results of a Randomized-Controlled Equivalence Trial 2021 ·JCO Global Oncology ·(unknown), (unknown), Philip R. Debruyne, Hans Pottel, Veerle Foulon, (unknown), (unknown), (unknown), Dominique Vandijck, Koen Van Eygen	4
4	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP 2021 ·Blood Advances ·Sophie Bernard, Hervé Ghesquières, Olivier Casasnovas, (unknown), María Gomes da Silva, Pierre Feugier, Franck Morschhauser, (unknown), Loïc Renaud, Richard Greil, Alejandro Martı́n, Sebastian Grosicki, Koen Van Eygen, Christiane Copie‐Bergman, Corinne Haïoun, Catherine Thiéblemont	7
5	Detection of alcohol abuse in older patients with cancer: The integration of alcohol screening questionnaires in the comprehensive geriatric assessment 2019 ·Journal of Geriatric Oncology ·Michelle Lycke, (unknown), (unknown), (unknown), (unknown), Hans Pottel, Koen Van Eygen, (unknown), Patricia Schofield, Tom Boterberg, Philip R. Debruyne	3
6	An observational pilot study to evaluate the feasibility and quality of oncological home-hospitalization 2019 ·European Journal of Oncology Nursing ·(unknown), (unknown), Dominique Vandijck, (unknown), Michelle Lycke, (unknown), Philippe Vergauwe, Veerle Foulon, Hans Pottel, Philip R. Debruyne, Koen Van Eygen	14
7	The added value of an assessment of the patient's hand grip strength to the comprehensive geriatric assessment in G8-abnormal older patients with cancer in routine practice 2019 ·Journal of Geriatric Oncology ·Michelle Lycke, (unknown), (unknown), (unknown), Hans Pottel, Koen Van Eygen, (unknown), Lies Pottel, Cindy Kenis, Patricia Schofield, Tom Boterberg, Philip R. Debruyne	10
8	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study 2019 ·The Lancet Haematology ·Franck Morschhauser, Steven Le Gouill, Pierre Feugier, Sarah Bailly, Emmanuelle Nicolas‐Virelizier, Fontanet Bijou, Gilles Salles, Hervé Tilly, Christophe Fruchart, Koen Van Eygen, Sylvia Snauwaert, Christophe Bonnet, Corinne Haïoun, Catherine Thiéblemont, Réda Bouabdallah, Ka Lung Wu, Danielle Canioni, Véronique Meignin, Guillaume Cartron, Roch Houot	61
9	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium 2019 ·Acta Haematologica ·Timothy Devos, Gregor Verhoef, (unknown), Dominiek Mazure, Philippe Lewalle, Dominique Bron, Zwi Berneman, Fleur Samantha Benghiat, Philippe Mineur, Koen Theunissen, Pierre Zachée, Chantal Doyen, (unknown), Marie Lejeune, Koen Van Eygen, Violaine Havelange, (unknown), (unknown), (unknown)	4
10	Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study 2019 ·Journal of Geriatric Oncology ·(unknown), (unknown), Michelle Lycke, Lies Pottel, (unknown), (unknown), (unknown), (unknown), Hans Pottel, Karin Stellamans, Koen Van Eygen, Patrick Werbrouck, Philippe Vergauwe, Hans Wildiers, Patricia Schofield, Tom Boterberg, Philip R. Debruyne	15
11	Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients 2019 ·Journal of Psychosocial Oncology ·Michelle Lycke, (unknown), Lies Pottel, Hans Pottel, (unknown), Karin Stellamans, Koen Van Eygen, Philippe Vergauwe, Patrick Werbrouck, (unknown), Tom Boterberg, (unknown), Patricia Schofield, Philip R. Debruyne	22
12	Organization, quality and cost of oncological home-hospitalization: A systematic review 2018 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), Philip R. Debruyne, (unknown), (unknown), Michelle Lycke, (unknown), Hans Pottel, Veerle Foulon, Koen Van Eygen	20
13	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey 2017 ·European Journal Of Haematology ·Timothy Devos, Yves Béguin, Lucien Noens, Koen Van Eygen, Pierre Zachée, Philippe Mineur, Laurent Knoops, Chantal Doyen, Koen Theunissen, Fleur Samantha Benghiat, (unknown), (unknown)	4
14	Oncological Home-Hospitalization: Prospective randomized trial to evaluate its implications for patient and society 2017 ·Annals of Oncology ·(unknown), (unknown), Philip R. Debruyne, Kurt Geldhof, (unknown), (unknown), Veerle Foulon, Hans Pottel, Dominique Vandijck, Koen Van Eygen	0
15	Implementation of uHear™ - an iOS-based application to screen for hearing loss - in older patients with cancer undergoing a comprehensive geriatric assessment 2016 ·Journal of Geriatric Oncology ·Michelle Lycke, Tom Boterberg, (unknown), (unknown), Hans Pottel, (unknown), Koen Van Eygen, (unknown), Ingeborg Dhooge, Hans Wildiers, Philip R. Debruyne	15
16	Practical management of Chronic Myeloid Leukemia in Belgium 2015 ·Open Repository and Bibliography (University of Liège) ·(unknown), Yves Béguin, Barbara Dessars, Timothy Devos, Philippe Lewalle, Philippe Mineur, Nicole Straetmans, Koen Van Eygen, G. Verhoef, L. Knoops	1
17	Myelofibrosis patients in Belgium: disease characteristics 2014 ·Acta Clinica Belgica ·Timothy Devos, Pierre Zachée, Dominique Bron, Lucien Noens, Jan Van Droogenbroeck, Philippe Mineur, Yves Béguin, Zwi Berneman, Fleur Samantha Benghiat, Alain Kentos, C Chatelain, H Demuynck, Jan Lemmens, Koen Van Eygen, Koen Theunissen, Fabienne Trullemans, P. Pierre, (unknown), L. Knoops	6
18	Could the combined test "VES-13 + (max - G8)" represent an interesting alternative screening tool for identification of potential vulnerable elderly head and neck cancer patients? 2011 ·Journal of Geriatric Oncology ·Lies Pottel, Tom Boterberg, Hans Pottel, Laurence Goethals, Nele Van Den Noortgate, Fréderic Duprez, Wilfried De Neve, Sylvie Rottey, Kurt Geldhof, Koen Van Eygen, (unknown), Véronique Ghekiere, Frank Cornélis, Supriya G. Mohile, Philip R. Debruyne	2
19	NONADHERENCE WITH IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA IS A FUNCTION OF DISEASE, HEALTH, KNOWLEDGE, AND SOCIAL FACTORS - RESULTS FROM THE ADAGIO STUDY 2008 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), Lucien Noens, (unknown), G. Verhoef, Pierre Zachée, Zwi Berneman, (unknown), (unknown), Koen Van Eygen, (unknown), (unknown), Sabina De Geest, Tara Albrecht, Ivy Abraham	3
20	Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection 1995 ·Gastrointestinal Endoscopy ·C. Ramboer, (unknown), (unknown), (unknown), Koen Van Eygen, (unknown)	88

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact